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Background: Sleep disturbances are among the most common non-motor symptoms of Parkinson’s disease (PD),
greatly interfering with daily activities and diminishing life quality. Pharmacological treatments have not been
satisfactory because of side effects and interactions with anti-parkinsonian drugs. While studies have shown
that regular exercise improves sleep quality in normal aging, there is no definitive evidence in PD.
Methods: In a retrospective study, we determined whether an intense physical and multidisciplinary exercise
program improves sleep quality in a large group of patients with PD.
We analyzed the scores of PD Sleep Scale (PDSS), which was administered twice, 28 days apart, to two groups of
patients with PD of comparable age, gender, disease duration and pharmacological treatment. The control group
(49 patients) did not receive rehabilitation, The treated group (89 patients) underwent a 28-day multidisciplinary
intensive rehabilitation program (three one-hour daily sessions comprising cardiovascular warm-up, relaxation,
muscle-stretching, balance and gait training, occupational therapy to improve daily living activities).
Results: At enrolment, control and treated groups had similar UPDRS and PDSS scores. At re-test, 28 days
later, UPDRS and total PDSS scores improved in the treated (p < 0.0001) but not in the control group. In particular,
the treated group showed significant improvement in PDSS scores for sleep quality, motor symptoms and daytime
somnolence. The control group did not show improvement for any item.
Conclusions: These results suggest that multidisciplinary intensive rehabilitation treatment may have a positive impact
on many aspects of sleep in PD.
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Sleep disturbances are among the most common non-
motor symptoms of Parkinson’s disease (PD). Their
prevalence ranges from 40% to 90%, depending upon the
type of study, and they include insomnia, excessive day-
time sleepiness, REM sleep behavior disorder, restless legs
and sleep apnea [1,2]. Sleep problems greatly interfere
with daily activities and diminish the quality of life of the
patients and their caregivers. Unfortunately, these symp-
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unless otherwise stated.medications [3], and the pharmacological treatments have
not produced satisfactory results [4,5]. Similarly, alterna-
tive approaches, such as repetitive transcranial magnetic
stimulation, have been proven ineffectual [6].
In physiological aging, sleep complaints have been ad-
dressed mostly pharmacologically, but also with alterna-
tive or complementary strategies such as exercise: studies
in normally aging subjects have indeed shown that sleep
quality improves following regular exercises of moderate
intensity [7,8]. There are increasing evidence that physical
exercise of different sort and intensity can produce clinical
benefits and might improve the general life quality of pa-
tients with PD [9,10]. Only few studies show a possible
benefit of physical exercise on sleep in PD. Nascimento
et al. demonstrated that a multimodal exercise program
seem to be a feasible and effective alternative to decreasel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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disease [11]. However, this exercise program is not specific
for PD, no objective measures (i.e. physical performance
test) were included, and the used scale for the assessment
of sleep-related disorder (Mini-Sleep Questionnarie) [12]
is not properly suitable for PD. Recently, Wassom DJ et al.
determined the impact of a six-week Qigong exercise
intervention as a potential complementary therapy in the
management of sleep-related symptoms in PD. Following
Qigong, subjects showed improvement in some aspects of
sleep quality [13]. However this is a very small (seven pa-
tients) and uncontrolled study. Other promising indica-
tions come from a study showing that scores improved in
several areas related to quality of life, including sleep, fol-
lowing a twelve-week exercise program [14]. However,
also this study was uncontrolled and, most importantly,
it used a non-PD specific scale (the Nottingham Health
Profile) [15], in which sleep quality, one of six items, was
tested with questions that did not address the specific
problems of PD.
PD Sleep Scale (PDSS) [16] is a visual analogue scale
with 15 questions related to sleep problems that are
commonly associated with PD, such as REM behavior
disorders and nocturnal motor symptoms. In the last ten
years, PDSS has been developed, tested and used in pa-
tients with PD in different types of studies [6,17,18]. Im-
portantly, PDSS has good test–retest reliability and it has
been validated in different populations of PD patients, in-
cluding an Italian population [17].
It has been demonstrated that the physical treatments
specifically made for PD should be multidisciplinary and
have certain characteristics of intensity in order to be ef-
fective [9,10].
In this retrospective study, we examined PDSS scores
to verify the effects of a four-week multidisciplinary in-
tensive rehabilitation program on the sleep quality in a
large group of patients with PD.
Methods
Patients
We retrospectively analyzed data from our prospectively
collected database of patients with PD. We studied 138
patients (61 men, mean age ± SD: 69.1 ± 7.4 years) be-
longing to two groups: Group 1- patients who under-
went multidisciplinary intensive rehabilitation treatment
(MIRT, 89 patients); Group 2- patients who were kept
on pharmacological therapy only (Controls, 49 patients).
All patients had a diagnosis of “clinically probable” idio-
pathic PD [19]; Hoehn-Yahr stage 2 or 3; Mini-Mental
State Examination score > 26; subjective complaints of
sleep disturbances; ability to walk without physical assist-
ance; ability to perceive visual and auditory cues. Also, they
did not have any other neurological conditions, postural
hypotension, cardiovascular disorders, musculoskeletaldisorders, vestibular dysfunction limiting locomotion or
balance. All patients had scores less than 8 at the Hamilton
Depression scale.
This is a retrospective study based on our prospect-
ively collected institutional database.
The Local Ethics Committee of Ospedale Moriggia-Pelascini
approved the study. All patients provided written consent
to the scientific treatment of their data in an anonymous
form at the time of the assessment.
MIRT protocol
MIRT had been described in detail in previous papers
[10,20-22]. It is specifically designed for PD. Briefly, it
consisted of a 4-week physical therapy that entailed three
daily sessions, five days a week, in a hospital setting. The
duration of each session, including recovery periods, was
about one hour. The first session comprised cardiovas-
cular warm-up activities, relaxation, muscle-stretching
(scapular, hip flexor, hamstring and gastrocnemius mus-
cles), exercises to improve the range of motion of spinal,
pelvic and scapular joints, exercises to improve the func-
tionality of the abdominal muscles, and postural changes
in the supine position. The second session included exer-
cises to improve balance and gait using a stabilometric
platform with visual cues (patients had to follow a circular
pathway on a screen by using a cursor sensitive to their
feet movements on the platform) and treadmill plus
(treadmill training with both visual and auditory cues)
[23]. All the exercise on the treadmill were aerobic with a
hearth rate reserve 60% to 70% and a maximum speed of
treadmill scrolling of 3.5 km/h. The last was a session of
occupational therapy to improve autonomy in day living
activities: transferring from sitting to standing, rolling
from supine to sitting position and viceversa, dressing, use
of tools, exercises to improve hand functionality and
visuo-motor skills. The rehabilitation program, consider-
ing individually each patient, could also include: speech
therapy, hydrotherapy (for severe disorders of balance and
posture), and robotic-assisted walking training for specific
gait disorders (i.e. freezing of gait).
Outcome measures
In both groups, we analyzed UPDRS III and II scores
measured at enrolment and 28 days later, always at
10 AM, by the same neurologist, expert in movement
disorders and blind with respect to the study design. Al-
though UPDRS is a scale with some limitations (i.e. the
low emphasis on the non-motor features of PD), we
used this scale to establish the effect of MIRT on activ-
ities of daily life and on motor clinical aspects of the dis-
ease. These data were important in order to evaluate the
correlations between the motor performance and the
sleep parameters. Sleep complaints were assessed with
an Italian translation of the PDSS [17]. Chaudhuri et al.
Table 1 Average scores (±SD) and percentage of patients
with abnormal scores (<8)
Item Mean Score ± SD Abnormal Score (%)
1 6.5 ± 2.6 57.2
2 6.6 ± 3.3 50.7
3 6.0 ± 3.2 65.2
4 7.3 ± 3.3 37.7
5 7.3 ± 3.1 42.8
6 8.4 ± 2.4 21.7
7 9.6 ± 1.3 5.1
8 4.2 ± 3.1 83.3
9 7.1 ± 3.4 39.9
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strument for measuring sleep disturbances in PD [16].
Each of the items or questions was scored on a scale be-
tween 0 (always suffer from the disorder) and 10 (never
suffers the disorder). The PDSS items were also grouped
into sub-domains or categories of sleep-related disor-
ders; sleep quality (items 1–3), nocturnal restlessness
(item 4 and 5), nocturnal distressing dreams and halluci-
nations (item 6 and 7), nocturia (item 8), nocturnal motor
off and sensory symptoms (items 9–13), and daytime som-
nolence (item 14 and 15). Classification of patients with
nocturnal symptoms was based on a pre-specified cutoff
score of less than or equal to 100; single items with a score
below 8 were considered as “sleep disturbances” [16,24].10 7.6 ± 2.7 40.6
11 7.2 ± 2.9 47.8
12 7.3 ± 3.3 37.0
13 8.0 ± 2.9 27.5
14 7.2 ± 3.0 42.8
15 8.7 ± 1.9 26.1Statistical analysis
Descriptive statistics are reported as mean ± SD. Shapiro–
Wilk statistic was used to assess the normality of the dis-
tribution of all variables. To ascertain whether MIRT
improved sleep quality, we used a mixed model ANOVA
with Group (MIRT; Control) as between factor and Time
(baseline, 28 days later) as within factor, and post-hoc
tests. Correlations between PDSS, clinical and demo-
graphic data were assessed by the Pearson R coefficient. A
p-value < 0.05 was considered statistically significant.Results
PDSS at enrolment: characteristics of sleep in PD
Analyses on the combined group of 138 patients (MIRT:
89; Controls: 49) showed that, at enrolment, disease
duration was 9.3 years (±3.3, SD); levodopa equivalent
medication 611.5 mg (±341.8), Hoehn & Yahr stage
2.61 (±0.48), UPDRS II scores 11.4 (±5.5) and UPDRS
III scores 14.87 (±7.1). On average, the total score of PDSS
was 109.03 (±23.77) with 32% of the patients (44 in total,
36 in group 1 and 8 in group 2) having a total PDSS less or
equal to 100. Table 1 reports average scores and percent-
ages of patients with abnormal scores (<8) for each PDSS
item. In general, these results were similar to the ones re-
ported previously in different PD studies [16-18,24], with
item 8 (nocturia) having the lowest scores and the greatest
percentage of patients with abnormal scores.
We then correlated the global PDSS scores with the
clinical and demographic data. Briefly, PDSS scores
showed significant inverse correlation with UPDRS II
scores (r = −0.29, p = 0.0005) and with the amount of
levodopa equivalent therapy (r = −0.24, p = 0.005). No
significant correlation was found between PDSS scores
and age, gender, disease duration and UPDRS III scores.
Between-group comparisons at enrolment revealed no
significant differences for disease duration (9.1 ± 3.6 vs.
9.7 ± 2.7 years, p = 0.32); levodopa equivalent medication
(581.1 ± 351.7 vs. 666.8 ± 319.3 mg, p = 0.2), Hoehn &Yahr stage (2.61 ± 0.52 vs. 2.61 ± 0.44, p = 0.999) and
UPDRS III scores (14.33 ± 5.97 vs. 15.86 ± 8.76, p = 0.23).
The mean ± SD and the percentage of patients with
abnormal scores (<8) for of each of the PDSS items are
reported for each group in Figure 1 and Table 2. Briefly,
at enrolment, there was no significant difference be-
tween the total scores (106.67 ± 27.29 vs. 113.3 ± 14.79,
p = 0.12). However, we found between-group differences
for some items: restlessness (item 4, MIRT < Controls, p
= 0.013), nocturia (item 8, MIRT > Controls, p = 0.009),
incontinence (item 9, MIRT < Controls, p = 0.01), numb-
ness during sleep (item 10, MIRT < Controls, p = 0.04),
pain at awakening (item 12, MIRT < Controls, p = 0.04),
tiredness in the morning (item 14, MIRT < Controls, p =
0.0008), daytime sleepiness (item 15, MIRT > Controls,
p = 0.05). Nevertheless, the scores’ profiles of the two
groups were similar, with item 8 (nocturia) having the
lowest scores and item 7 (hallucinations) the greatest
scores (Figure 1).
MIRT improves UPDRS scores and sleep quality
In both groups, pharmacological therapy did not change
during the twenty-eight day period and it was the same
at both testing times, thus ruling out a possible effects
related to drug changes. Twenty-eight days after the
baseline, UPDRS scores significantly decreased in the
MIRT group (UPDRS III: 14.33 ± 5.97 vs. 8.34 ± 5.36 p <
0.0001; UPDRS II: 11.29 ± 4.88 vs. 6.63 ± 3.96, p < 0.0001),
while they did not change in the controls (UPDRS III:
15.8 ± 8.76 vs. 15.65 ± 8.48, p = 0.23; UPDRS II: 11.69 ±
5.36 vs. 11.49 ± 6.44, p = 0.42).
Figure 1 Scores (mean ± SD) for PDSS items at baseline (white columns) and four weeks later (black columns). A. Multidisciplinary
intensive rehabilitation treatment (MIRT) group; B. Control group.Asterisks over columns and framed titles indicate significant score changes for
single and grouped items, respectively. Thick dotted lines represent minimum normal scores.
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nificant interaction between Groups and Time (Group: F
(1,136) = 0.025, p = 0.88; Time: F(1,136) = 18.22; p <
0.0001; TimeXGroup: F(1,1) = 21.40; p < 0.0001), sug-
gesting a significant change in the MIRT group only. OnTable 2 Percentage of patients with abnormal scores (<8)
Group 1 Group 2
Item PRE POST Difference PRE POST Difference
1 55.06 49.44 5.62 61.22 61.22 0
2 50.56 40.45 10.11 51.02 48.98 2.04
3 62.92 53.93 8.99 69.39 67.35 2.04
4 43.82 28.09 15.73 26.53 28.57 −2.04
5 39.33 22.47 16.85 48.98 48.98 0
6 22.47 20.22 2.25 20.41 20.41 0
7 5.62 6.74 −1.12 4.08 4.08 0
8 75.28 71.91 3.37 97.96 97.96 0
9 44.94 37.08 7.87 30.61 30.61 0
10 40.45 31.46 8.99 40.82 44.90 −4.08
11 47.19 22.47 24.72 48.98 48.98 0
12 40.45 31.46 8.99 30.61 32.65 −2.04
13 30.34 24.72 5.62 22.45 24.49 −2.04
14 51.69 35.96 15.73 26.53 26.53 0
15 20.22 13.48 6.74 36.73 36.73 0average, in the MIRT group, PDSS scores increased from
106.67 (±27.29) to 118.4 (±20.27; p < 0.0001), while they
slightly decreased in the controls (from 113.3 ± 14.79 to
112.84 ± 14.78; p = 0.03). Also, as shown in Table 2 for
each item, the percentage of patients with abnormal
scores decreased in MIRT group and remained the same
in the controls. In Figure 1, we report the scores of each
item, separately and grouped by category, for the two
groups at the two time points. Analysis of individual
scores revealed that, in MIRT group, significant improve-
ment occurred for almost all the items, with the exclusion
of: items 7 (distressing hallucinations during the night)
and 15 (daytime sleepiness), which had already average
scores close to 10 before treatment; items 8 (nocturia) and
12 (painful posture in the morning), which showed only
trends to improvement. In the controls, no statistical
changes were noted, with the exception of a mild worsen-
ing for item 7 (from 9.63 ± 0.97 to 9.53 ± 1.0, p = 0.024).
Thus, in summary, improvement in MIRT group was sig-
nificant for the sensori-motor symptoms and restlessness
(Group: F(1, 138) = 1.63, p = 0.2; Time: F(1, 138) = 4.14;
p = 0.04; TimeXGroup: F(1,1) = 5.93; p = 0.0031; post-hoc:
MIRT: p < 0.0001, controls: p = 0.24); the quality of sleep
items (Group: F(1, 138) = 0.22, p = 0.64; Time: F(1, 138) =
9.17; p = 0.0029; TimeXGroup: F(1,1) = 8.49; p = 0.0042;
post-hoc: MIRT: p < 0.0001, controls: p = 0.32); day-
time somnolence (Group: F(1, 138) = 0.85, p = 0.36;
Frazzitta et al. Journal of Clinical Movement Disorders  (2015) 2:11 Page 5 of 8Time: F(1, 138) = 4.3; p = 0.04; TimeXGroup: F(1,1) = 3.8;
p = 0.049; post-hoc: MIRT: p < 0.0088; controls: p = 0.32).
We then verified whether the improvement in the gen-
eral quality of sleep in the MIRT group was triggered by
improvement in other categories or items: there were no
significant correlations between improvements in any of
the items or category and the quality of sleep. Neverthe-
less, we found significant correlations between improve-
ments in nocturnal sensory-motor symptoms and daytime
somnolence (r = 0.39; p = 0.001) as well as between rest-
lessness (item 4 and 5) and distressing hallucinations dur-
ing the night (r = 0.38; p = 0.001).
Finally, we found significant correlations in MIRT group
between the changes in the PDSS total scores and in the
UPDRS III and II scores (PDSS and UPDRS III: r = 0.26
p = 0.009; PDSS and UPDRS II: r = 0.35, p = 0.005). When
we verified these correlations for each of the PDSS cat-
egories (Table 3), we found that sleep quality significantly
correlated with the changes in UPDRS total and UPDRS
II scores, as well as with the performance on the 6-minute
walking time test. Improvement in the sensory-motor
nocturnal symptoms instead significantly correlated with
PDDS changes, while decrease in restlessness correlated
with improvement in the total UPDRS scores.
While the total scores and the PDSS general profiles
were similar in the two groups at baseline, there were
significant between-group differences for some of the
PDSS items. Since the control group had greater scores
closer to the normal range, although unlikely, over time
improvement in this group could have been prevented
by a ceiling effect. Thus, we selected a subgroup of con-
trols with abnormal PDSS scores (<8) in at least one
item at baseline and matched them with subjects of
MIRT group by PDSS scores, UPDRS scores, age, and
levodopa equivalents. This procedure left us with 30
subjects per group. ANOVAs comparing the effect of ex-
ercise and group revealed results similar to those ob-
tained with the entire groups: for the total PDSS scores
we found a significant interaction between Groups and
Time (Group: F(1, 58) = 3.6, p = 0.064; Time: F(1, 58) =
36.3; p < 0.0001; TimeXGroup: F(1,1) = 41.8; p < 0.0001),
showing again a significant score improvement in theTable 3 Correlations between improvements in PDSS








UPDRSTot 0.32* 0.08 0.20 0.05 0.29*
UPDRS_III 0.11 −0.07 0.01 −0.06 0.11
UPDRS_II 0.28* 0.07 0.14 0.07 0.21
PDDS 0.07 0.09 0.35* 0.10 0.21
sixMWT −0.26* 0.04 −0.17 −0.16 −0.11
*Significant correlation between improvements in PDSS category and clinical
scores (r values).MIRT group only. These results further suggest that ab-
sence of improvement in the control group is not due to
a “ceiling” effect.
Discussion and conclusions
The main result of this study is that a four-week inten-
sive rehabilitation treatment in patients with PD has a
positive effect on the sleep quality measured with PDSS,
a scale that specifically addresses the sleep complaints of
this disease. Second, the significant correlation between
the improvements in UPDRS II and PDSS scores con-
firms that sleep plays an important role in improving au-
tonomy in daily living activities and quality of life in
patients with PD. Third, the finding of a significant inverse
correlation between levodopa equivalents and PDSS scores
suggests that increase of dopaminergic therapy has a nega-
tive impact on the quality of sleep of patients with PD.
Altogether, these results suggest that sleep is an important
factor in determining quality and autonomy in daily living
activities in PD and that increasing levodopa levels might
have a negative effect on sleep quality. Our data coincide
with those recently appeared in recent studies showing
that dopaminergic treatment decreases subjective and ob-
jective indices of sleep quality [25]. For instance, dopamin-
ergic medication is thought to have a desynchronizing
effect on sleep architecture that causes disruption of sleep
continuity leading to excessive daytime sleepiness and
“sleep attacks” [26]. Finally, these results confirm previous
findings about the profile of the PDSS scores [15] in a dif-
ferent Italian population and suggest that PDSS yields
highly reproducible results at one-month retest in the
control group.
MIRT has a positive effect on sleep quality and on
nocturnal motor symptoms
As in previous studies [10,20,22], UPDRS II and III scores
significantly decreased after MIRT, while they did not
change in the control group after a similar time interval.
The novel finding is that the scores of PDSS, a scale
geared to measure sleep problems that are specific to PD,
also improved following MIRT. The most significant ef-
fects were seen in the general quality of sleep, nocturnal
motor symptoms and daytime somnolence.
A few papers have already reported that exercise has a
positive effect on the general quality of sleep in elderly
normal subjects [7,8]. This is the first study in a large
PD population showing that, besides improving the gen-
eral quality of sleep, exercise decreases the severity of
the nocturnal symptoms that are typical of this disease.
Although improvements in those two categories could
be related, as the general quality of sleep might benefit
from decreased severity of nocturnal parkinsonian symp-
toms, we did not find any significant correlation between
them. Nocturnal motor and sensory-related symptoms
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cramps, are characteristically found in a majority of pa-
tients with PD and are responsible for frequent arousals
and disruption of sleep. The origins of the specific noc-
turnal symptoms as well as of problems falling asleep
and maintaining sleep are still obscure, mostly because the
effects of multiple factors with a possible causal role cannot
be disentangled. In fact, on one side, the disease is accom-
panied by the degeneration of the brainstem regulatory
centers of sleep and wakefulness; on the other, dopamin-
ergic treatment contributes to exacerbating sleep problems.
What could be the mechanisms behind this exercise-
related improvement?
It is possible that the general improvement in several as-
pects of motor performance, measured with the UPDRS
III scores, might lead to a reduction of nocturnal hypoki-
nesia resulting in both an enhancement of sleep quality
and a reduction of sensory-motor nocturnal symptoms.
However, although nocturnal hypokinesia might be a
major determinant of sleep quality [27], we did not find
significant correlations between improvements in PDSS
and UPDRS III scores. We instead found significant corre-
lations between improvements in the scores of PDSS
and UPDRS II, which reflect autonomy in daily living
activities. Although we cannot establish direct causal-
ity between sleep improvement and quality of daytime
life, undoubtedly, exercise improves the quality of both
sleep and daytime life, with a significant gain in personal
autonomy.
Therefore, we found that MIRT significantly improved
the sleep quality of Parkinsonian patients. Although fur-
ther studies are needed, these results strongly suggest
that exercise should be included in the management of
sleep disturbances in PD.
The effects of MIRT on sleep might be linked to enhanced
brain plasticity
A rather speculative interpretation of the mechanisms of
MIRT effects on sleep quality might come from a recently
formulated hypothesis, the synaptic homeostasis hypoth-
esis [28], that provides a crucial link between plasticity-
related phenomena and sleep. Briefly, this hypothesis states
that during wake, activity induces long term potentiation
(LTP)-related processes resulting in synaptic strength in-
creases, which, in turn, promote sleep and, in particular,
slow wave activity, the most restorative part of sleep. The
function of slow wave activity is to renormalize, off-line,
the synaptic weight and to restore the proper function,
counteracting all costs of wake, both at cellular, system,
and behavioral levels. Thus, more efficient are the LTP-
related phenomena and the synapses strengthening during
the day, greater is the slow wave activity during sleep. In-
deed, exercise enhances the mechanisms related to brain
plasticity, with positive effects on dopaminergic andglutamatergic neurotransmission [29], striatal upregulation
of brain-derived neurotrophic factor (BDNF) and glial cell
line-derived neurotrophic factor in rat models of PD [30],
hippocampal neurogenesis in normal mice [31], increased
levels of peripheral BDNF in the elderly [32] and in pa-
tients in the early PD stages [33].
In patients with PD, electrophysiological and behav-
ioral induction of LTP-like phenomena in the cortex
seems impaired, with decreased potentiation phenomena
[34-36] and decreased retention of new skills [30,37,38].
In addition, slow wave activity during sleep is reduced in
patients with PD [26]. We thus might speculate that exer-
cise, by enhancing LTP-related phenomena and promot-
ing plasticity during wakefulness, might trigger a more
restorative sleep. Indeed, prospective studies are needed to
verify this hypothesis and to determine whether exercise
produces improvements in LTP-related mechanisms and
whether this improvement induces, in turn, changes in
the sleep electroencephalography.
Study limitations
This study was based on retrospective analysis of a pro-
spectically collected data-base. Even though this study de-
sign might constitute a potential limitation, we think that
our results would not change significantly in a controlled
study since data collection procedures were carefully de-
signed and all relevant information were recorded on a
structured protocol.
Although in this study was demonstrated a significant
inverse correlation between levodopa equivalents and
PDSS scores, the confounding effects of PD medications
on sleep has not been completely addressed. Sleep distur-
bances in PD are dose related [39]: low-dose dopamine ag-
onists have been associated with insomnia, whereas higher
doses can lead to excessive daytime sleepiness. While ini-
tially associated with dopamine agonists, these symptoms
can be induced by levodopa as well [3].
Limitations also include the different environmental con-
ditions for the two groups. In fact, patients in the MIRT
group were hospitalized for the entire 28-day period, while
the controls were not. However, while hospitalization gen-
erally worsens sleep, in our study we have found an im-
proving in sleep quality at the end of MIRT.
Another limitation arises from the difficulty to discern
the effects related to the generic exercise and those dir-
ectly attributable to MIRT. It is common opinion that bet-
ter results in Parkinsonian patients have achieved using
training program with a high training intensity, “beyond
what they may self-select” [40], and with a multidisciplin-
ary approach [41]. The aim of the study was to evaluate
the efficacy of MIRT in Parkinsonian patients in compari-
son to patients treated only with drugs. The next step will
be planning a study with a comparison between two dif-
ferent rehabilitation treatments.
Frazzitta et al. Journal of Clinical Movement Disorders  (2015) 2:11 Page 7 of 8A last criticism is the possible placebo effect of re-
habilitation. The strength of expectation of clinical im-
provement during a rehabilitation or pharmacological
treatment influences per se the release of dopamine [42].
This is another aspect that has to be clarified in a future
study comparing two different rehabilitation treatments
and providing for a follow-up period.
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